Navigation Links
Poniard Pharmaceuticals Reports Third Quarter 2010 Financial Results
Date:11/9/2010

$7.9 million, compared to $18.5 million for the same period in 2009.

General and administrative expenses were $5.1 million for the quarter ended September 30, 2010, compared to $4.1 million for the quarter ended September 30, 2009. Year to date, general and administrative expenses were $13.7 million compared to $10.9 million for the same period in 2009. The increase in both periods was primarily attributable to increased accounting and legal fees associated with our evaluation of potential strategic alternatives and to increased share-based compensation for the year to date period.

Cash and investment securities as of September 30, 2010, were $23.3 million, compared to $43.4 million at December 31, 2009. Management currently believes that the existing cash and investment securities will provide adequate resources to fund operations at least through the end of 2010.

Conference Call DetailsPoniard's management team will host a conference call and Webcast today at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time. To participate in the call by telephone, please dial 866-804-6921 (United States) or 857-350-1667 (International). The passcode for the conference call is 12705036. In addition, the call is being Webcast and can be accessed on the "Events" page of the "News & Events" section of the Company's Web site at http://www.poniard.com. A replay of the Webcast will be available on the Company's Web site for 10 days.

About Poniard PharmaceuticalsPoniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products. For additional information please visit http://www.poniard.com.

Forward-Looking StatementsThis release contains forward-looking statements describing, among other things, the Company's projected financial position and future operations, the adequacy of its cash resources,
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Sept. 23, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a primary focus on China ... Shrotriya , MD, Chairman and Chief Executive Officer of ... appointment was made in connection with the recently announced ...
(Date:9/23/2014)...  Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the ... address unmet medical needs in the areas of ... has appointed Rasappa Arumugham , PhD, as ... has over 25 years of diverse experience in ... of formulation research, analytical method development, quality control ...
(Date:9/23/2014)... Sept. 23, 2014  As physicians seek information ... communication channels to learn about new therapies or ... from a new report by global sales and ... that communicating via a customized mix of digital ... best opportunity to engage with physicians. And, productive ...
Breaking Medicine Technology:CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 2CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 3CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 4Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development 2Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development 3Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development 4As sales reps see doors close for in-person visits with physicians, digital doors open communication 2As sales reps see doors close for in-person visits with physicians, digital doors open communication 3As sales reps see doors close for in-person visits with physicians, digital doors open communication 4As sales reps see doors close for in-person visits with physicians, digital doors open communication 5
(Date:9/23/2014)... Karen Pallarito HealthDay Reporter ... if doctors and hospitals got paid for providing better ... better data for making informed health choices. A ... is headed. The report, from the IMS Institute for ... -- recent events expected to alter the delivery of health ...
(Date:9/23/2014)... Avid collector Andrew Hawley, from Vintage Rock ... Auditorium Seattle concert posters. The Doors were a smash hit ... year. The Seattle Eagles Auditorium concert was held on July ... to Eagles Auditorium in November the same year. The artist ... comes in three colors. The poster is a split fountain ...
(Date:9/23/2014)... 23, 2014 (HealthDay News) -- Few children ... undergo behavioral therapy, and the rates vary six-fold ... study finds. Medication alone can manage symptoms ... better if they also receive behavioral therapy (psychotherapy), ... analyzed data in more than 1,500 counties across ...
(Date:9/23/2014)... the benefits of preventing a reduction in the ... released today by the American College of Physicians ... the Medicaid Primary Care Pay Parity Program: Unless ... Primary Care Will Expire," explains why it is ... and pediatricians (and their related subspecialists), family physicians, ...
(Date:9/23/2014)... 23, 2014 The global ... (AR) is highly fragmented, with the US, ... available, under different regulatory restrictions, with almost ... has the most developed market, with subcutaneous ... immunotherapy tablets (AITs) all being available. However, ...
Breaking Medicine News(10 mins):Health News:Report Identifies Game Changers for U.S. Health Care 2Health News:Report Identifies Game Changers for U.S. Health Care 3Health News:Kids Taking ADHD Drugs Get Little Psychotherapy: Study 2Health News:Unless Congress acts, patients may soon lose access to primary care 2Health News:Unless Congress acts, patients may soon lose access to primary care 3Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 4
... rehabilitation professionals expect 20-plus percent employment increases through 2016. ... ... September 8, 2008 -- People reach significant milestones through ... the http://www.nraf-rehabnet.org/ [National Rehabilitation Awareness Foundation], which ...
... Common painkillers like aspirin and ibuprofen appear to lower a ... to help gauge whether a man is at risk of ... appears online Sept. 8 in the journal Cancer , ... to prevent prostate cancer just yet. , "We showed ...
... Pa., Sept. 5 Lieutenant Governor,Catherine Baker Knoll today ... Blood Donor Day., The Commonwealth of Pennsylvania and ... to give blood in commemoration of those who lost ... supplies. One blood,donation can save up to three lives., ...
... John McCain to commit to develop a National AIDS,Strategy ... Sep. 5 The,Republican National Convention concluded last night ... United States and only passing reference to,the epidemic overseas. ... Gov. Sarah Palin mentioned AIDS in their remarks,to Convention ...
... 5 On Saturday, September 6, PARI,Respiratory Equipment will ... part of their "Breathe Easier" series. PARI is highlighted ... as COPD,sufferers, with effective nebulizers and compressors that deliver ... to improve the lives of those affected by respiratory,diseases ...
... disease resistance to anti-hormonal therapy , , FRIDAY, Sept. ... help "re-sensitize" certain breast cancer tumors to anti-hormonal ... , Women with estrogen-receptor or progesterone-receptor positive (ER ... anti-hormonal medicines, such as aromatase inhibitors, to keep ...
Cached Medicine News:Health News:U.S. Demand for Rehabilitation Professionals Grows 2Health News:U.S. Demand for Rehabilitation Professionals Grows 3Health News:Common painkillers lower levels of prostate cancer biomarker 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3Health News:PARI Respiratory Equipment Featured on Oxygen Network 2Health News:Drug Re-Sensitizes Breast Tumors to Treatment 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: